## UNITED STATES SECURITIES AND EXCHANGE COMMISSION
### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

---

**1. Name and Address of Reporting Person**
SHERMAN JEFFREY W
C/O HORIZON PHARMA PLC
CONNAUGHT HOUSE, 1ST FL, 1 BURLINGTON RD
DUBLIN L2 4

**2. Issuer Name and Ticker or Trading Symbol**
Horizon Therapeutics Public Ltd Co [HZNP]

**3. Date of Earliest Transaction (Month/Day/Year)**
05/11/2020

**4. If Amendment, Date of Original Filed (Month/Day/Year)**

**5. Relationship of Reporting Person(s) to Issuer**

- **Director**
- **10% Owner**
- **Officer (give title below)**
- **EVP and Chief Medical Officer**

**6. Individual or Joint/Group Filing (Check Applicable Line)**
X Form filed by One Reporting Person
Form filed by More than One Reporting Person

---

### Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>Title of Security (Instr. 3)</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Security Acquired (A) or Disposed Of (D) (Instr. 4)</th>
<th>Amount (A) or (D) (Instr. 5)</th>
<th>Price (In $)</th>
<th>Relationship of Reporting Person(s) to Issuer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ordinary Shares</td>
<td>05/11/2020</td>
<td></td>
<td>M</td>
<td>33,479</td>
<td>$4.96</td>
<td>EVP and Chief Medical Officer</td>
</tr>
<tr>
<td>Ordinary Shares</td>
<td>05/11/2020</td>
<td></td>
<td>S(1)</td>
<td>33,479</td>
<td>$45</td>
<td>EVP and Chief Medical Officer</td>
</tr>
</tbody>
</table>

**7. Nature of Indirect Beneficial Ownership (Instr. 4)**
By Trust

---

### Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<table>
<thead>
<tr>
<th>Title of Derivative Security (Instr. 3)</th>
<th>Conversion or Exercise Price of Derivative Security</th>
<th>Transaction Date (Month/Day/Year)</th>
<th>Deemed Execution Date, if any (Month/Day/Year)</th>
<th>Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 4)</th>
<th>Date Exercisable (Month/Day/Year)</th>
<th>Expiration Date (Month/Day/Year)</th>
<th>Title of Derivative Security (Instr. 5)</th>
<th>Amount or Number of Shares (A) or (D)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stock option (right to buy)</td>
<td>$4.96</td>
<td>05/11/2020</td>
<td>(1)</td>
<td>33,479</td>
<td>12/08/2021</td>
<td>Ordinary Shares</td>
<td>33,479</td>
<td>$0.00</td>
</tr>
</tbody>
</table>

**Explanation of Responses:**
1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2020.
2. The stock option is fully vested and exercisable.

**Remarks:**

---

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

**Signature of Reporting Person**

**Date**

---

**Miles W. McHugh**
Attorney-in-Fact
05/12/2020

**OMB APPROVAL**
OMB Number: 3235-0287
Estimated average burden hours per response: 0.5